ArticleJHEP reports : innovation in hepatology2026
Zinc finger protein 544 promotes hepatocellular carcinoma by generating an immunosuppressive tumor microenvironment.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsThis study identified zinc finger protein 544 (ZNF544) as a biomarker in hepatocellular carcinoma (HCC) and aims to delineate its functional role.
methodsThe correlation between ZNF544 expression and clinical parameters of patients with HCC (n = 50) and the malignant biological behavior of HCC cells was analyzed in vitro (n = 5/group) and in vivo (n = 10/group).
resultsZNF544 was elevated in tumors of patients with HCC (p = 0.0006). Patients with HCC exhibiting high ZNF544 expression was associated with a more advanced clinical stage (p = 0.0026) and showed greater infiltration of M2 macrophages (p = 0.0031) and Tregs (p = 0.0094). ZNF544 knockdown inhibited the pro-angiogenic ability of HCC cells (p <0.01). Increased ZNF544 expression accelerated the growth of orthotopic tumors (increased >80%, p <0.0001) and the infiltration of M2 macrophages (increased >60%, p = 0.0008) and Tregs (increased >80%, p = 0.0029) within the orthotopic tumors, and accelerated lung metastasis (number of mice with lung metastasis increased >160%). ZNF544 bound to the spermatogenesis-associated serine-rich protein 2 (SPATS2) promoter and activated its transcription, whereas SPATS2 enhanced the triosephosphate isomerase (TPI1) mRNA stability. ZNF544 promoted glycolysis in HCC cells in a SPATS2-dependent manner. SPATS2 knockdown suppressed glycolysis in HCC cells and inhibited orthotopic tumor growth, which was rescued by TPI1 overexpression. Ivermectin was identified as a pharmacological inhibitor of ZNF544, effectively suppressing the progression of HCC.
conclusionsZNF544 accelerates HCC by activating SPATS2/TPI1 and promoting glycolysis and immune escape. Targeting ZNF544, including compounds such as ivermectin, may offer a preliminary avenue for further investigation in HCC. IMPACT AND IMPLICATIONS: This research underscores the role of ZNF544-SPATS2 as a pivotal regulator of TPI1 expression in HCC. TPI1 shapes the immunosuppressive TME and accelerates growth and metastasis by promoting glycolysis and facilitating the infiltration of M2 macrophages and Tregs. Our research suggests that ZNF544 could serve as a novel biomarker for HCC, and the pharmacological inhibitor of ZNF544, ivermectin, emerges as a promising therapeutic option for HCC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.